Advanz Pharma
↗London, United Kingdom
Advanz Pharma is a British multinational specialty pharmaceutical company headquartered in London, UK, operating globally with commercial presence in over 90 countries. The company was formerly known as Concordia Healthcare Corp. before rebranding in November 2018. Acquired by Nordic Capital Fund X Epsilon in June 2021 for $846 million, Advanz Pharma focuses on specialty, hospital, and rare disease medicines across multiple therapeutic areas. The company operates through a lean infrastructure model, partnering with CMOs and CDMOs for manufacturing while maintaining centers of excellence in London, Mumbai, Sydney, Dublin, Helsingborg, and Chicago. With 717 employees and annual revenues around $185-525M, Advanz Pharma has become a significant player in European specialty pharmaceuticals and biosimilar commercialization.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals, Biosimilars, Rare Diseases
SIZE & FINANCIALS
Employees:501-1000
Revenue:$185M-$525M
Founded:1963
Ownership:private
Status:operating
FUNDING
Stage:Private Equity Backed
Total Raised:$846M
Investors:Nordic Capital Fund X Epsilon
PIPELINE
Stage:Commercial|Phase 2|Phase 3
Lead Drug Stage:Commercial (multiple approved products)
Modalities:Small molecule, Specialty generics, Biosimilars, mAb, Originator brands
Active Trials:100
Trial Phases:-
FDA Approvals:0
EMA Approvals:3
CORPORATE STRUCTURE
Parent Company:Cidron Aida Bidco Limited (Nordic Capital fund subsidiary)
Acquired By:Nordic Capital Fund X Epsilon (Cidron Aida Bidco Limited) (2021-06-01)
Subsidiaries:Correvio Pharma Corp, Intercept subsidiaries (ex-US operations)
Key Partnerships:Alvotech (exclusive commercialization rights for multiple biosimilar candidates), Applied Therapeutics (AT-007/Govorestat commercialization in Europe), GP Pharm (peptide specialty injectable generics agreement), Multiple CMOs/CDMOs for manufacturing
COMPETITION
Position:Challenger
Competitors:Sandoz (biosimilars), STADA Arzneimittel, Blue Earth Diagnostics, Beaphar UK, Vitaflo International, Other specialty pharma and generic manufacturers
LEADERSHIP
Key Executives:
Steffen Wagner - Chief Executive Officer
Andreas Stickler - Chief Financial Officer
Susanna El-Armale - Chief Corporate Development Officer
Chris Britten - Senior Vice President, M&A
Anke Niedernberg - Senior Vice President, Head of Transformation Office
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Advanz Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Advanz Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.